CeleCor Therapeutics develops a RUC-4 novel small molecule inhibitor designed to be the first point of contact treatment for segment elevated myocardial infarction. The molecule inhibitor uses a thrombolytic agent for percutaneous coronary intervention that can be administered subcutaneously by auto-injector, enabling decreased mortality and laterdevelopment of heart failure.

Biotechnology

Health Care

Therapeutics

CeleCor Therapeutics

Robert S. Hillman

Karlien Lubberink

Peter Finn

Oana Cociorva

Marijo Gleeson

Barry S. Coller

The Advisory Team at CeleCor Therapeutics provides expert guidance on the development, clinical trials, and regulatory strategies for the RUC-4 small molecule inhibitor, leveraging their collective experience to optimize its efficacy and safety for treating segment elevated myocardial infarction.

Advisory Team

Leadership Team

Advisory Team

About

Team members

Other teams at CeleCor Therapeutics

Leadership Team